Author(s):
Varun Sureja, Dharmesh Kumar Kheni, Shrikalp Deshpande
Email(s):
rxvarun@gmail.com
DOI:
10.52711/0974-360X.2026.00562 
Address:
Varun Sureja*, Dharmesh Kumar Kheni, Shrikalp Deshpande
Faculty of Pharmaceutical Science, Kadi Sarva Vishwavidyalaya, Gandhinagar, Gujarat, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 9,
Year - 2026
ABSTRACT:
Background: Inflammatory bowel disease (IBD) is one of the highly prevalent chronic inflammatory disease conditions leading to symptoms like abdominal pain, bloody diarrhea, and anaemia. While numerous studies have demonstrated beneficial effect of probiotics therapy in IBD condition, studies evaluating the impact of storage conditions on the efficacy of probiotics in IBD condition is lacking. Objectives: The aim of the current study was to evaluate the efficacy of probiotic (Lactobacillus rhamnosus) stored at different storage conditions in dinitrobenzene sulfonic acid (DNBS) induced colitis in Albino Wistar rats. Methods: L. rhamnosus probiotic was stored at 25°C±60% RH and 40°C±75% RH for 12 months. Representative sample of storage conditions at baseline, months 6 and 12 were collected and the efficacy was evaluated in experimental colitis model. Male albino Wistar rats were administered single-dose DNBS (120mg/kg/rat) intra-rectally for colitis induction. Rats were randomised into groups to receive either saline, dexamethasone, or probiotics from different storage conditions for 28days following colitis induction. Evaluation parameters included body weight, average food and water intake, colon weight and damage level (using the colonic mucosal damage index (CMDI) and disease activity index (DAI) scores), serum analysis (nitric oxide (NO), malondialdehyde (MDA), glutathione (GSH) and superoxide dismutase (SOD) levels), and fecal calprotectin level. Results: Probiotics and dexamethasone therapy significantly prevented colitis induced intestinal damage with dexamethasone therapy being superior to probiotics therapy for all evaluated parameters. A progressive reduction in probiotics efficacy was observed with difference in temperature and duration of storage conditions. Compared to baseline probiotics therapy, probiotics stored at 25°C and 40°C for 6 and 12 months showed reduced efficacy in preventing intestinal damage, reducing oxidative stress and inflammation levels. Conclusion: Using experimental model of colitis, the results of current study highlights the importance of optimal storage conditions on the viability and overall efficacy of probiotics. It can be concluded that optimal storage conditions for maintaining probiotic viability is essential to ensure therapeutic benefits to the recipient.
Cite this article:
Varun Sureja, Dharmesh Kumar Kheni, Shrikalp Deshpande. Effect of different storage conditions on the efficacy of Probiotic Lactobacillus rhamnosus in experimental DNBS-induced Colitis in rats. Research Journal Pharmacy and Technology. 2026;19(9):4005-3. doi: 10.52711/0974-360X.2026.00562
Cite(Electronic):
Varun Sureja, Dharmesh Kumar Kheni, Shrikalp Deshpande. Effect of different storage conditions on the efficacy of Probiotic Lactobacillus rhamnosus in experimental DNBS-induced Colitis in rats. Research Journal Pharmacy and Technology. 2026;19(9):4005-3. doi: 10.52711/0974-360X.2026.00562 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-9-8
REFERENCES:
1. Ramos GP, Papadakis KA. Mechanisms of disease: Inflammatory bowel diseases. Mayo Clin Proc. 2019; 94(1): 155–65.
2. Zhang YZ, Li YY. Inflammatory bowel disease: Pathogenesis. World J Gastroenterol. 2014; 20(1): 91–9.
3. Vermeire S, Assche G Van, Rutgeerts P. Classification of inflammatory bowel disease: the old and the new. Curr Opin Gastroenterol. 2012; 28(4): 321–6.
4. Ray G. Inflammatory bowel disease in India - Past, present and future. World J Gastroenterol. 2016; 22(36): 8123–36.
5. Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: The great shift east. Inflamm Intest Dis. 2017; 2(2): 102–15.
6. Dam AN, Berg AM, Farraye FA. Environmental influences on the onset and clinical course of Crohn’s disease—Part 1: An overview of external risk factors. Gastroenterol Hepatol. 2013; 9(11): 711–7.
7. Davis J, Kellerman R. Gastrointestinal conditions: Inflammatory bowel disease. FP Essent. 2022; 516: 23–30.
8. Singh S, Blanchard A, Walker JR, Graff LA, Miller N, Bernstein CN. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2011; 9(9): 769–75.
9. Duff W, Haskey N, Potter G, Alcorn J, Hunter P, Fowler S. Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance. World J Gastroenterol. 2018; 24(28): 3055–70.
10. Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther. 2016; 7(1): 5–20.
11. Kheni DB, Sureja VP, Deshpande SS, Dubey VP, Kansagra JJ. A systematic mapping review of in-vitro and in-vivo evidences exploring the role of strain-specific probiotic Bifidobacterium longum W11. Int J Pharm Sci Drug Res. 2024; 16(1): 127–34.
12. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World J Gastroenterol. 2015; 21(29): 8787–803.
13. Santana PT, Rosas SLB, Ribeiro BE, Marinho Y, Souza HS de. Dysbiosis in inflammatory bowel disease: Pathogenic role and potential therapeutic targets. Int J Mol Sci. 2022; 23(7): 3464.
14. Dahal RH, Kim S, Kim YK, Kim ES, Kim J. Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis. Front Microbiol. 2023; 14: 1174832.
15. Shan Y, Lee M, Chang EB. The gut microbiome and inflammatory bowel diseases. Annu Rev Med. 2022; 73: 455–68.
16. Lal S, Kandiyal B, Ahuja V, Takeda K, Das B. Gut microbiome dysbiosis in inflammatory bowel disease. Prog Mol Biol Transl Sci. 2022; 192(1): 179–204.
17. Bhagat B, Jagtap A, Hapse S, Pagar H, Wagh A, Kale N. Formulation and evaluation of probiotic gel containing anti-inflammatory agent for treatment of IBDS. Res J Pharm Technol. 2012; 5(3): 387–9.
18. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014; 11(5): 4745–67.
19. Ma T, Shen X, Shi X, Sakandar HA, Quan K, Li Y, et al. Targeting gut microbiota and metabolism as the major probiotic mechanism - An evidence-based review. Trends Food Sci &Technology. 2023; 138: 178–98.
20. Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of probiotics on gut microbiota: An overview. Int J Mol Sci. 2024; 25(11): 6022.
21. Li C, Niu Z, Zou M, Liu S, Wang M, Gu X, et al. Probiotics, prebiotics, and synbiotics regulate the intestinal microbiota differentially and restore the relative abundance of specific gut microorganisms. J Dairy Sci. 2020; 103(7): 5816–29.
22. Zam W, Dawod R. Overview of the probiotics’ role in gastrointestinal disorders. Res J Pharm Technol. 2020; 13(11): 5557–61.
23. Swathi K. Probiotics - A human friendly bacteria. Res J Pharm Technol. 2016; 9(8): 1260–2.
24. Shinde N, Bangar B, Deshmukh S, Kumbhar P. Nutraceuticals: A review on current status. Res J Pharm Technol. 2014; 7(1): 110–3.
25. Thakur S, Srivastava N. Nutraceuticals: A review. Asian J Res Pharm Sci. 2016; 6(2): 85–94.
26. Lokhande S, More S, Raje V. A systematic study of probiotics- An update review. Asian J Pharm Technol. 2018; 8(3): 149–57.
27. Beevi SS, Pottakkat B, Narayanan S. Role of probiotics and gut microbiota in liver diseases. Asian J Nurs Educ Res. 2023; 13(2): 157–61.
28. Jannah SR, Rahayu ES, Yanti R, Suroto DA, Wikandari R. Study of viability, storage stability, and shelf life of probiotic instant coffee Lactiplantibacillus plantarum subsp. plantarum Dad-13 in vacuum and nonvacuum packaging at different storage temperatures. Int J Food Sci. 2022;2022:1663772.
29. Mortazavian A, Ehsani M, Mousavi S, Rezaei K, Sohrabvandi S, Reinheimer J. Effect of refrigerated storage temperature on the viability of probiotic micro-organisms in yogurt. Int J Dairy Technol. 2007; 60(2): 123–7.
30. Cabello-Olmo M, Oneca M, Torre P, Díaz JV, Encio IJ, Barajas M, et al. Influence of storage temperature and packaging on bacteria and yeast viability in a plant-based fermented food. Foods. 2020; 9(3): 302.
31. Ahn SI, Cho S, Choi NJ. Effect of dietary probiotics on colon length in an inflammatory bowel disease-induced murine model: A meta-analysis. J Dairy Sci. 2020; 103(2): 1807–19.
32. Zhang T, Zhang J, Duan L. The role of genetically engineered probiotics for treatment of inflammatory bowel disease: A systematic review. Nutrients. 2023; 15(7): 1566.
33. Huan Y, Peng S, Zeng R, Yao H, Feng G, Fang J. From probiotic chassis to modification strategies, control and improvement of genetically engineered probiotics for inflammatory bowel disease. Microbiol Res. 2024; 289: 127928.
34. Pesce M, Seguella L, Re A Del, Lu J, Palenca I, Corpetti C, et al. Next-generation probiotics for inflammatory bowel disease. Int J Mol Sci. 2022; 23(10): 5466.
35. Sundaramoorthy S, Selvaraj S, Kameshwari V. Antibacterial activity of Lactobacillus species isolated from dairy products against antibiotics. Res J Pharm Technol. 2020; 13(8): 3915–7.
36. Chauhan SB, Singh V, Chauhan R. Effect of encapsulated Lactobacillus rhamnosus GG in antibiotic associated diarrhea in Albino Wistar rat model. Res J Pharm Technol. 2020; 13(12): 5736–42.
37. Burayev G, Khamitov M, Lozovoy V, Aipov R, Lozovaya E, Akhmaltdinova L, et al. The correction methods of the intestinal microflora in chronic colonic stasis by Siphon enema and probiotics as a means of the Hirschsprung-associated Enterocolitis prevention. Res J Pharm Technol. 2020; 13(6): 2601–7.
38. Jaleel S, Kiliç AO. Antimicrobial action of isolated probiotic Lactobacillus plantarum from different fermented dairy products from Trabzon city. Res J Pharm Technol. 2020; 13(5): 2445–51.
39. Chauhan A, Kaur S, Singh R. A review on probiotics and fish farming. Res J Pharm Technol. 2018; 11(11): 5143–6.
40. Moorthy MK, Nayak BK, Nanda A. Antioxidant and antitumor activity of lactic bacteria isolated from natural beverage - Coconut toddy. Res J Pharm Technol. 2017; 10(12): 4317–20.
41. Achanta H, Suneetha V. Isolation and biochemical characterization of probiotic Lactobacillus species isolated from curd samples of southern regions of Vellore, Tamil Nadu. Res J Pharm Technol. 2017; 10(6): 1734–41.
42. Hossain MK, Nahar K, Shokryazdan P, Abdullah N, Hamid K, Jahromi MF. Probiotic potential of lactic acid bacteria isolated from cheese, yogurt and poultry faeces. Res J Pharm Technol. 2017; 10(9): 2991–8.
43. Abraham N, Namachivayam C, Sundaramoorthy S. Lactobacillus - An friendly bacteria. Int J Technol. 2021; 11(2): 70–7.
44. Kheni DB, Sureja VP, Deshpande SS, Dubey VP, Kansagra JJ, Bariya AH. Efficacy evaluation of probiotic Lactobacillus rhamnosus suspension formulated with medium chain triglycerides oil in DNBS-induced colitis in Sprague-Dawley rats. Int J Pharm Sci Drug Res. 2025; 17(2): 185–93.
45. Maciel-Fiuza MF, Muller GC, Campos DMS, Costa P do SS, Peruzzo J, Bonamigo RR, et al. Role of gut microbiota in infectious and inflammatory diseases. Front Microbiol. 2023; 14: 1098386.
46. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018; 361: k2179.
47. Sharifi-Rad J, Rayess Y El, Rizk AA, Sadaka C, Zgheib R, Zam W, et al. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Front Pharmacol. 2020; 11: 01021.
48. Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao F, et al. The emerging role of oxidative stress in inflammatory bowel disease. Front Endocrinol (Lausanne). 2024; 15: 1390351.
49. Liu P, Li Y, Wang R, Ren F, Wang X. Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease. Biomedicines. 2021; 10(1): 85.
50. Morgan MJ, Liu Z gang. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011; 21(1): 103–15.
51. Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov. 2009; 3(1): 73–80.
52. Ramos-González EJ, Bitzer-Quintero O, Ortiz G, Hernández-Cruz J, Ramírez-Jirano L. Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. Neurologia. 2024; 39(3): 292–301.
53. Abdolmaleky HM, Zhou JR. Gut microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. Antioxidants. 2024; 13(8): 985.
54. Li L, Peng P, Ding N, Jia W, Huang C, Tang Y. Oxidative stress, inflammation, gut dysbiosis: What can polyphenols do in inflammatory bowel disease? Antioxidants. 2023; 12(4): 967.
55. Li Q, Zheng T, Ding H, Chen J, Li B, Zhang Q, et al. Exploring the Benefits of Probiotics in Gut Inflammation and Diarrhea—From an Antioxidant Perspective [Internet]. Antioxidants. mdpi.com; 2023. Available from: https://www.mdpi.com/2076-3921/12/7/1342
56. Ballini A, Santacroce L, Cantore S, Bottalico L, Dipalma G, Topi S, et al. Probiotics efficacy on oxidative stress values in inflammatory bowel disease: A randomized double-blinded placebo-controlled pilot study. Endocr Metab Immune Disord Drug Targets. 2019; 19(3): 373–81.
57. Cordiano R, Gioacchino M Di, Mangifesta R, Panzera C, Gangemi S, Minciullo PL. Malondialdehyde as a potential oxidative stress marker for allergy-oriented diseases: An update. Molecules. 2023; 28(16): 5979.
58. Aquilano K, Baldelli S, Ciriolo MR. Glutathione: new roles in redox signaling for an old antioxidant. Front Pharmacol. 2014;5:196.
59. Younus H. Therapeutic potentials of superoxide dismutase. Int J Health Sci (Qassim). 2018; 12(3): 88–93.
60. Korczowska-Łącka I, Słowikowski B, Piekut T, Hurła M, Banaszek N, Szymanowicz O, et al. Disorders of endogenous and exogenous antioxidants in neurological diseases. Antioxidants. 2023; 12(10): 1811.
61. Moura FA, Andrade KQ de, Santos JCF dos, Araújo ORP, Goulart MOF. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol. 2015; 6: 617–39.
62. Wang Y, Wu Y, Wang Y, Xu H, Mei X, Yu D, et al. Antioxidant properties of probiotic bacteria. Nutrients. 2017; 9(5): 521.